XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
License and Agreements (Details) - USD ($)
1 Months Ended 3 Months Ended
Aug. 12, 2020
May 31, 2020
Jan. 31, 2020
Jan. 31, 2019
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Nov. 24, 2019
Mar. 31, 2018
License and Agreements (Details) [Line Items]                  
Assignment fee                 $ 100,000
Milestone fee               $ 50,000  
Accounts payable due         $ 35,000   $ 21,000    
Research and development cost expenses         1,585,000 $ 1,812,000      
Pre-marketing approvals $ 25,000,000                
Recorded research and development costs         5,261,604 5,278,252      
Interest fee         500,000        
Other receivable         1,776,583   1,628,703    
Master Services Agreement [Member]                  
License and Agreements (Details) [Line Items]                  
Agreement term, description       the Company cancelled all of the individual study contracts with ITR and entered into contracts with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (“SPI”)) and 11035835 Canada Inc., (dba Periscope Research) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.          
Accounts payable due         472,000   0    
Clinical Network Services Pty Ltd. [Member]                  
License and Agreements (Details) [Line Items]                  
Agreement description     to provide initial contract clinical research and development services for the Company’s drug product candidates. The accounts payable due in connection with this agreement was approximately AUD$179,000 (US$134,000) and AUD$138,000 (US$100,000) as of March 31, 2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately AUD$347,000 (US$251,000) and AUD$705,000 (US$545,000), respectively, pertaining to this agreement.            
Clinical trial research agreement with Nucleus Network Pty Ltd. [Member]                  
License and Agreements (Details) [Line Items]                  
Agreement description   to provide a Phase I study of one of the Company’s drug candidates, Tacrolimus. The accounts payable due in connection with this agreement was approximately $0 and AUD$161,000 (US$117,000) as of March 31, 2022 and December 31, 2021, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded research and development costs of approximately $0 and AUD$244,000 (US$188,000), respectively, pertaining to this agreement.              
Contract manufacturing services [Member] | Master Services Agreement [Member]                  
License and Agreements (Details) [Line Items]                  
Accounts payable due         14,000        
Recorded research and development costs         226,000        
April 2019 [Member]                  
License and Agreements (Details) [Line Items]                  
Research and development cost expenses         446,000 494,000      
January 2021 [Member]                  
License and Agreements (Details) [Line Items]                  
Research and development cost expenses         318,000 196,000      
January 2021 [Member] | Master Services Agreement [Member]                  
License and Agreements (Details) [Line Items]                  
Accounts payable due         87,000   $ 313,000    
Research and Development Expense [Member]                  
License and Agreements (Details) [Line Items]                  
Research and development expense         $ 147,880 $ 76,200